BLOG: The Endothelium: Getting to the “Heart” of Cardiovascular Disease

Despite positive developments in medication and lifestyle changes to reduce risk factors associated with cardiovascular disease (CVD) and atherosclerosis (plaque build-up in arteries), stroke and heart attack remain the leading cause of death worldwide. Innovation in medical care and medical devices will likely play a central role in improving long term cardiovascular health outcomes. Over

Read More

Lexington Biosciences Receives HeartSentry USPTO Patent Approval

Patent encompasses functional claims, underlying science and methods   VANCOUVER, British Columbia, July 25, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device. “Today’s news is a big deal for

Read More

Lexington Biosciences Announces Results of Annual General Meeting

VANCOUVER, British Columbia, July 02, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the results of its recent Annual General Meeting. The Company is pleased to announce that all matters before the Board were approved at the Company’s Annual General Meeting (the “AGM”) held

Read More

Lexington Biosciences Concludes Initial HeartSentry Clinical Study

Company prepares for multicenter pivotal clinical study VANCOUVER, British Columbia, June 27, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research. “We are pleased with the performance of the

Read More

BLOG: Medtech Innovation Improving and Saving Lives

At Lexington Biosciences, we are passionate believers in medical technology (medtech) as a way of improving healthcare and quality of life for all.  Similarly, well known consumer brand giants are also gravitating towards the medtech space.  Just like us, they see a chance to help humanity and address a market that is nothing shy of

Read More

BLOG: Lexington Biosciences Applauds ACA and AHA Initiative to Lower Threshold for Hypertension and Recognition that More Diagnostics are Needed to Combat Heart Disease

Last November, the American College of Cardiology and American Heart Association jointly lowered their definition of hypertension from the previous 140/90 blood pressure reading down to 130/80.  Unfortunately, there isn’t necessarily a “one size fits all” standard due to an array of factors associated with high blood pressure, but there certainly is a well-known correlation

Read More

Lexington Biosciences Announces Amended Terms to Previously Announced Brokered Financing

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, June 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”) announces that it has amended the terms of its previously announced brokered private placement being led by Gravitas Securities Inc. and Canaccord Genuity Corp. (the “Agents”) (see news release

Read More

BLOG: You Don’t Want Your First Sign of a Problem to be a Heart Attack

Nearly everyone has a story about someone close to them that passed away suddenly due to cardiac arrest, or someone who had a stroke that left them disabled, no longer the person they were the day before.  Management here at Lexington Biosciences is no different.  Our founders and leadership team have also gotten that gut-wrenching

Read More

Article: Lexington Biosciences is Set to Help Predict Cardiovascular Disease

Lexington Biosciences Inc. (CSE:LNB) (OTC:LXGTF) plans to commercialize an at-home product to better predict whether a person is at risk for cardiovascular disease Angela Harmantas | May 31, 2018 | SmallCapPower: Cardiovascular disease is leading cause of death in North America, and yet, nearly one-third of those deaths are preventable. Annually, over 1.5 million people

Read More

1 2 3 4



Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News